Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06922630

WIN: a Feasibility Study of a Weight-Neutral Health Intervention

The WIN intervention aims to improve the mental, social and physical health as well as quality of life of participants with BMI≥30 without focusing on their weight, and with no aim of weight loss. The WIN 6 months intervention is based on the principles and methods of the weight neutral movement Health at Every Size (HAES). The content is developed in a co-design process that involved Danish participants who have lived or professional experiences with such approaches.

The intervention uses the method of intuitive eating to align eating behaviours with internal cues of hunger and fullness rather than rules, restrictions and external cues. The intervention also draws on components from Acceptance and Commitment Therapy (ACT) to manage body image concerns and weight stigma.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Research Unit for General Practice and Section of General Medicine, Department of Public Health, University of Copenhagen

Copenhagen, Denmark

About this study

The WIN group intervention comprises bi-weekly two-hour sessions with 11-12 participants and two WIN-therapists. Session 1 is an individual session and sessions 2-12 are group sessions. The programmes include psychoeducation, group discussions and homework about topics within the weight neutral approach such as intuitive eating, weight stigma, enjoyable movement and self-compassion.

Overview of sessions 1-12:

  • Individual session with a WIN therapist to explore the participant's expectations and needs in relation to commencing intuitive eating and body acceptance.
  • Introduction to weight-neutral health
  • Your body, Your rules
  • Intuitive eating I
  • Intuitive eating II
  • Body Respect and Weight Stigmatization
  • Self-compassion and confronting your inner critical voice
  • Body awareness, Rest and Movement - Yoga and Your strong body
  • Body awareness, Rest and Movement, intimacy and sexuality
  • Follow-up on intuitive eating
  • Follow-up on challenges
  • Strategies for resilience

Optional WIN elements include two support network events, up to 24 2-hour sessions of WIN-physical activity (Rest and Movement (12 sessions) and Competent Body Training (12 sessions)), and three individual online sessions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old at screening.
  • BMI ≥30 kg/m2.
  • Residence in the Capital Region of Denmark.
  • Able to understand and communicate in Danish.
  • Informed consent.

Exclusion criteria

  • Intends to become pregnant during the intervention or is currently pregnant.
  • Has used weight loss medications or GLP-1 agonist treatment within the past 6 months or intends to use weight loss medications or begin any other intensive weight loss treatment during the WIN intervention.
  • Has severe psychiatric or physical conditions that may interfere with participation or may present a safety concern.
  • Cannot transport themselves to the group sessions.
  • Is deemed unable to complete a two-hour group session, as assessed by the investigator at the clinical screening interview.
  • Takes part in other research involving weight loss treatment that would compromise participation in this study.

Treatment and study plan

WIN

Behavioral

Weight-neutral health intervention

Primary outcomes

  1. Primary feasibility outcome: completion of follow-up

    Time frame: 24 weeks after inclusion

    The proportion of participants who complete the follow-up examination, defined as answering the 'Mental health component' of the 36-item Short Form survey

Secondary outcomes

  1. Secondary feasibility outcome: recruitment proportion

    Time frame: Inclusion

    The proportion of people who are enrolled as participants (numerator, n) out of all those who passed the initial telephone screening (denominator, N).

  2. Secondary feasibility outcome: fidelity midway

    Time frame: After group session 5 (study week 12)

    Proportion of sessions attended by participants compared to the total number of sessions available

  3. Secondary feasibility outcome: fidelity end of intervention

    Time frame: After group session 11 (study week 23)

    Proportion of sessions attended by participants compared to the total number of sessions available

Other outcomes

  1. Exploratory feasibility outcomes: Completion of follow-up, individual questionnaires

    Time frame: End of study (week 24)

    Proportion of participants that complete all questionnaires required in CID1 and CID2, see list below (all outcomes specified as 'exploratory clinical outcome, questionnaire')

  2. Exploratory feasibility outcomes: Completion of follow-up, blood samples

    Time frame: End of study (week 24)

    Proportion of participants willing to give blood samples at both CID1 and CID2

  3. Exploratory feasibility outcomes: Completion of follow-up, hair samples

    Time frame: End of study (week 24)

    Proportion of participants willing to give hair samples at both CID1 and CID2

  4. Exploratory feasibility outcomes: Completion of follow-up, actigraphy

    Time frame: End of study (week 24)

    Proportion of participants willing to wear an actigraphy measuring physical activity. Assessed as the proportion of participants willing to wear and returning the SENS monitor after both CID1 and CID2.

  5. Exploratory feasibility outcomes: Completion of follow-up, physical assessments

    Time frame: End of study (week 24)

    Proportion of participants participating in the physical assessments in both CID1 and CID2, see list below (all outcomes specified as 'exploratory clinical outcome, physical assessment')

  6. Exploratory feasibility outcomes: Compliance and participant engagement, 'rest and movement'

    Time frame: End of study (week 24)

    Proportion of participants participating in at least one of the optional sessions 'rest and movement'

  7. Exploratory feasibility outcomes: Compliance and participant engagement, 'competence and strength training'

    Time frame: End of study (week 24)

    Proportion of participants participating in at least one of the optional sessions 'competence and strength training'

  8. Exploratory feasibility outcomes: Compliance and participant engagement, 'support network events'

    Time frame: End of study (week 24)

    Proportion of participants participating in at least one of the optional 'support network events'

  9. Exploratory feasibility outcomes: Compliance and participant engagement, 'online sessions'

    Time frame: End of study (week 24)

    Proportion of participants who attends at least one online session with the WIN-group therapist

  10. Exploratory clinical outcome, questionnaire: SF-36 mental component score

    Time frame: End of study (week 24)

    Quality of life, Short Form 36, mental component score (scale from 0-100, higher scores indicate better mental health)

  11. Exploratory clinical outcome, questionnaire: SF-36 physical component score

    Time frame: End of study (week 24)

    Quality of life, Short Form 36, physical component score (scale from 0-100, higher scores indicate better mental health)

  12. Exploratory clinical outcome, questionnaire: SF-36 subscales

    Time frame: End of study (week 24)

    Quality of life, Short Form 36, individual domains (scales from 0-100, higher scores indicate better mental health):

    • physical functioning,
    • role limitations due to physical health problems,
    • bodily pain,
    • general health,
    • vitality (energy or fatigue),
    • social functioning,
    • role limitations due to emotional problems,
    • mental health (psychological distress and psychological well-being).
  13. Exploratory clinical outcome, questionnaire: Mental health - WBIS-M

    Time frame: End of study (week 24)

    Weight Bias Internalization Scale (WBIS-M) score (scale from 1-7, higher scores indicate higher degree of internalized weight bias)

  14. Exploratory clinical outcome, questionnaire: Intuitive Eating Scale - IES-3

    Time frame: End of study (week 24)

    Intuitive Eating Scale measuring participants' ability to rely on internal hunger and satiety cues, reject dieting mentally, and approach eating with body respect. 12 items, each scored 1-5. Minimum value 12, maximum value 60. Higher score reflects more intuitive eating (better outcome).

  15. Exploratory clinical outcome, questionnaire: Mental health - EDE-Q

    Time frame: End of study (week 24)

    Eating Disorder Examination Questionnaire (EDE-Q) score (scale from 0 to 6, higher scores indicate higher degree of eating disorder)

  16. Exploratory clinical outcome, questionnaire: Rosenberg Self-Esteem Scale

    Time frame: End of study (week 24)

    Rosenberg Self-Esteem Scale, measuring self-esteem levels as a psychological marker of well-being. 10 items, each scored 1-4. Minimum value 10, maximum value 40. Higher scores indicate higher self-esteem (better outcome).

  17. Exploratory clinical outcome, questionnaire: Body Appreciation Scale 2

    Time frame: End of study (week 24)

    Body Appreciation Scale 2 (BAS-2), assessing positive body image, focusing on body acceptance and appreciation. 10 items, each scored 1-5. Minimum value 10, maximum value 50. Higher score indicates higher body appreciation (better outcome).

  18. Exploratory clinical outcome, questionnaire: Cantril Ladder Scale

    Time frame: End of study (week 24)

    Cantril Ladder Scale, providing a subjective measure of life satisfaction and well-being. Range: 0-10. A ladder stretching from 0 at the bottom (worst possible situation) to 10 at the top (best possible situation). Higher score indicates a more positive evaluation of one´s life (better outcome).

  19. Exploratory clinical outcome, questionnaire: Major Depression Inventory (MDI)

    Time frame: End of study (week 24)

    Major Depression Inventory (MDI) (scale from 0-50, higher scores indicate more symptoms of depression)

  20. Exploratory clinical outcome, questionnaire: Perceived Stress Scale (PSS-10)

    Time frame: End of study (week 24)

    Perceived Stress Scale (PSS-10), measures perceived stress over the past month. 10 items, each scored 0-4. Minimum value 0, maximum value 40. Higher scores indicating higher perceived stress (worse outcome).

    (Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress.)

  21. Exploratory clinical outcome: physical activity, SENS

    Time frame: End of study (week 24)

    Assessed with activity tracker (SENS), measuring daily movement and exercise patterns (hours/day)

  22. Exploratory clinical outcome: sleep, SENS

    Time frame: End of study (week 24)

    Sleep duration using SENS Motion accelerometers (hours/day)

  23. Exploratory clinical outcome: chronic stress

    Time frame: End of study (week 24)

    Chronic stress (hair cortisol as a biomarker of long-term stress exposure)

  24. Exploratory clinical outcome, physical assessment: blood pressure

    Time frame: End of study (week 24)

    Systolic and diastolic blood pressure (mmHg)

  25. Exploratory clinical outcome, physical assessment: pulse

    Time frame: End of study (week 24)

    Pulse rate (beats per minute)

  26. Exploratory clinical outcome, physical assessment: weight

    Time frame: End of study (week 24)

    Weight (kg)

  27. Exploratory clinical outcome: Hb1Ac

    Time frame: End of study (week 24)

    Haemoglobin A1c (mmol/mol)

  28. Exploratory clinical outcome: lipids

    Time frame: End of study (week 24)

    Lipid profile (HDL, LDL, VLDL, total cholesterol and triglycerides) (mmol/L)

  29. Exploratory clinical outcome: creatinine

    Time frame: End of study (week 24)

    Creatinine (umol/L)

  30. Exploratory clinical outcome: eGRF

    Time frame: End of study (week 24)

    Estimated Glomerular Filtration Rate (eGFR) (mL/min/1.73^2)

  31. Exploratory clinical outcome: hsCRP

    Time frame: End of study (week 24)

    High-sensitivity C-reactive protein (hsCRP), mg/L

  32. Exploratory clinical outcome: ALAT

    Time frame: End of study (week 24)

    Alanine aminotransferase (ALAT) (unit per liter)

  33. Exploratory clinical outcome: TSH

    Time frame: End of study (week 24)

    Thyroid-stimulating hormone (x10^-3 IU/L)

  34. Exploratory clinical outcome: Sodium

    Time frame: End of study (week 24)

    Sodium (mmol/L)

  35. Exploratory clinical outcome: Potassium

    Time frame: End of study (week 24)

    Potassium (mmol/L)

  36. Exploratory clinical outcome: Haemoglobin

    Time frame: End of study (week 24)

    Haemoglobin (mmol/L)

  37. Exploratory clinical outcome: vitamin D

    Time frame: End of study (week 24)

    25-OH vitamin D (nmol/L)

  38. Exploratory clinical outcome: serious adverse event

    Time frame: End of study (week 24)

    Proportion of participants that experienced at least one serious adverse event (according to ICH-GCP guidelines)

  39. Other feasibility outcomes: Completion of follow-up, individual questionnaires

    Time frame: End of study (week 24)

    Proportion of participants that complete all questionnaires required in CID1 and CID2, see list below (all outcomes specified as 'exploratory clinical outcome, questionnaire')

Sponsors and collaborators

Lead sponsor

Carsten Dirksen

Other

Collaborators

  • Copenhagen Trial Unit, Center for Clinical Intervention Research
  • University of Copenhagen

Registry information

Official study title

WIN: a Feasibility Study of a Weight-Neutral Health Intervention. Lighthouse Consortium on Obesity Management (LightCOM) Trial no 1.

Acronym: WIN

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 10, 2025
Registry last updated
Dec 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.